The STEMI networks slide kit aims to establish an evidence-based, streamlined guidance on the purpose and practicality of establishing and running a STEMI network. It empowers HCPs with international guideline-based information to assist them in the process of setting up, organising, and participating in a regional STEMI network, in order to achieve optimal patient outcomes, and provides evidence from existing STEMI networks on protocols, challenges, solutions and outcomes.
STEMI basics including detailed epidemiology data, with trends across different populations, countries, ages and gender. Costs associated with acute myocardial infarction (AMI), global burden prediction for 2030, as well as EU forecast 2020 for healthcare costs are included. The pathophysiology section offers insight into risk factors (modifiable and non-modifiable), necrosis in MI, acute coronary syndrome and thrombus formation. A section on symptoms and diagnosis describes the STEMI types defined by ECG changes, diagnostic criteria and typical symptoms of acute myocardial infarction (AMI).
This slide kit contains highlights from the latest updated guidelines on the optimal management of STEMI. It includes a summary of the 2017 updated concepts in the ESC guidelines, as well as a comparison with the AHA 2015 guidelines. In addition to the recommendations on choice of reperfusion strategy between primary PCI and pharmaco-invasive therapy (fibrinolysis followed by early angiography within 2-24h or rescue intervention), the ESC 2017 STEMI guidelines recognise the gap between optimal and actual care, and the need for implementation of structural measures such as STEMI networks to improve patient outcomes.
A comprehensive slide kit highlighting the importance of improving time to treatment in STEMI, the strategies as well as guidelines needed for STEMI management. Several key factors on organisation and future improvements required in successfully sustaining STEMI networks are mentioned. Thrombolytic agents are reported and information about Metalyse® (tenecteplase) is also included. Important clinical outcomes and conclusions of studies such as the ASSENT trial series, FINESSE and DANAMI-2 are discussed. Key data from several registries (Vienna STEMI, Minneapolis STEMI & the French registries) are highlighted.
The slide kit describes STEMI pharmaco-invasive strategy, it’s importance as well as guidelines approved by international STEMI experts. Key details from several clinical studies (e.g. WEST, GRACIA-2, TRANSFER-AMI, NORDISTEMI, CAPTIM, STEPP-AMI, STREAM, EARLY-MYO) are reported. In addition, STEMI data from well-known registries is included with a summary of take home points.